CAS No.
[1231929-97-7 (Unlabeled)]
Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Refer MSDS for complete information
Synonyms
N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine-d10; N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine-d10
Application Notes
Useful research chemical for a range of applications
Hazard Compound
Refer MSDS for complete information
Abemaciclib-d10 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Abemaciclib-d10 usage and description
Abemaciclib D10 is a chemical compound that is used in the treatment of cancer. It is a potent and selective inhibitor of CDK4 and CDK6, which are enzymes that play a crucial role in cell division and proliferation. By inhibiting CDK4 and CDK6, Abemaciclib D10 prevents cancer cells from dividing and multiplying, thereby slowing down the growth and spread of cancer.
Abemaciclib D10 is typically administered orally in the form of tablets. The recommended dosage and duration of treatment vary depending on the type and stage of cancer being treated, as well as the patient's overall health and medical history. It is usually prescribed by a healthcare professional who specializes in cancer treatment.
In terms of chemical information, Abemaciclib D10 is a deuterated version of Abemaciclib, which means that some of its hydrogen atoms have been replaced with deuterium atoms. This modification does not affect the drug's efficacy but can improve its pharmacokinetic properties, such as absorption and distribution in the body.
Like all medications, Abemaciclib D10 may cause side effects. Common side effects include fatigue, diarrhea, nausea, decreased appetite, and infections. Patients should inform their healthcare provider if they experience any adverse effects while taking this medication.
In conclusion, Abemaciclib D10 is an important cancer treatment that works by inhibiting CDK4 and CDK6. It is typically administered orally and may cause side effects. Patients should follow their healthcare provider's instructions and report any adverse effects.
